Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NALIRIFOX + Iparomlimab + Tuvonralimab + SBRT as neoadjuvant therapy for resectable intrahepatic cholangiocarcinoma
ChiCTR2500115668Phase 4Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Dec 2025
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of NALIRIFOX, iparomlimab and tuvonralimab in intrahepatic cholangiocarcinoma (ICC), sponsored by West China Hospital of Sichuan University. Primary endpoint: R0 resection rate. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
NALIRIFOXiparomlimabtuvonralimab
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on ChiCTR2500115668.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500115668.